Helix BioPharma (HBP) AI Stock Analysis

• Market Cap: C$172.61M
• Dividend Yield: N/A
• Average Volume (3M): 13.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: N/A
• EPS Growth: 59.00%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 76,378,100
• 10 Day Avg. Volume: 29,165
• 30 Day Avg. Volume: 13,000
• PEG Ratio: 0.21
• Price to Book (P/B): 3.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: C$2.50 ▲(4.17% Upside)

The score is held down primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by a stronger balance-sheet position (low leverage) and improving loss/cash-flow trends. Technicals are supportive with the stock above key moving averages, while valuation is difficult to support due to losses and no dividend yield.

Positive Factors

Promising Clinical Findings

Positive clinical findings for L-DOS47 enhance Helix's potential to address unmet needs in oncology, supporting long-term competitive advantage.

Strategic Leadership Change

A new CEO with extensive oncology experience is likely to drive clinical advancements and strengthen Helix's market position in cancer treatment.

Leadership Strengthening

The appointment of experienced leaders is expected to enhance operational efficiency and stakeholder engagement, supporting long-term growth in the oncology sector.

Negative Factors

Negative Cash Flow

Persistent negative cash flow from operations underscores the unsustainable nature of Helix's business model without external funding.

Lack of Revenue

The absence of revenue generation highlights challenges in product commercialization, impacting long-term sustainability and market traction.

Financial Instability

Negative equity indicates financial instability, limiting Helix's ability to fund operations and invest in growth without external financing.

Helix BioPharma Business Overview & Revenue Model

Company Description

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

How the Company Makes Money

Helix BioPharma makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include potential partnerships and licensing agreements with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of successfully commercialized drugs. The company may also receive funding from government grants and research collaborations. Additionally, Helix BioPharma seeks to raise capital through equity financing to support its research and development efforts and progress its clinical trials.

Helix BioPharma Financial Statement Overview

Summary

Operating performance is very weak: no revenue, negative gross profit, and persistent net losses (TTM net loss ~4.9M). The balance sheet is a relative positive with modest leverage (TTM debt-to-equity ~0.02) and positive equity, but ongoing cash burn (TTM operating and free cash flow ~-4.2M) keeps funding risk elevated despite modest improvement versus 2024.

Income Statement

Across the period (including TTM (Trailing-Twelve-Months)), the company reports no revenue and persistent losses, with negative gross profit indicating ongoing operating costs without product sales. Losses remain sizeable (TTM net loss of ~4.9M), though the annual net loss improved versus 2024 (~9.3M), suggesting some cost containment. Overall profitability is still weak with no visible path to self-sustaining earnings in the reported figures.

Balance Sheet

Leverage is currently modest (TTM debt-to-equity ~0.02) with total debt (~0.35M) small relative to equity (~16.1M), which is a clear positive versus earlier years that showed negative equity (2021–2024) and, at times, high leverage (e.g., 2022). However, returns on equity are negative in the most recent periods due to ongoing net losses, and the historical swing from negative to positive equity highlights past balance-sheet stress and potential dilution/recapitalization risk.

Cash Flow

Cash generation remains negative, with TTM operating cash flow of about -4.2M and free cash flow also about -4.2M, implying continued cash burn to fund operations. Cash burn has improved versus 2024 (operating cash flow moved from about -5.2M to -4.2M), but operating cash flow still does not cover losses and the business remains reliant on external funding. Free cash flow largely tracks net loss, indicating limited non-cash offsets and no internally funded runway evident from these figures alone.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-10.00K	-14.00K	-13.00K	-12.00K	-173.00K
EBITDA	-5.21M	-9.38M	-6.31M	-6.03M	-9.46M
Net Income	-5.21M	-9.26M	-6.29M	-6.08M	-7.91M
Balance Sheet
Total Assets	18.80M	1.49M	1.03M	3.73M	4.07M
Cash, Cash Equivalents and Short-Term Investments	65.00K	1.08M	808.00K	3.25M	3.56M
Total Debt	335.00K	0.00	0.00	2.47M	3.61M
Total Liabilities	3.22M	1.58M	1.87M	3.41M	5.46M
Stockholders Equity	15.59M	-90.00K	-844.00K	319.00K	-1.39M
Cash Flow
Free Cash Flow	-3.83M	-5.23M	-5.54M	-6.51M	-9.30M
Operating Cash Flow	-3.83M	-5.22M	-5.53M	-6.51M	-9.30M
Investing Cash Flow	17.00K	-14.00K	-5.00K	0.00	2.02M
Financing Cash Flow	2.80M	5.51M	3.09M	6.21M	6.56M

Helix BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HBP, the sentiment is Positive. The current price of 2.4 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.26, and above the 200-day MA of 1.61, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of 74.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HBP.

Helix BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HBP	52 Neutral	C$172.61M	-27.57	-66.34%	―	―	59.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	$226.32M	-6.88	-89.10%	―	―	27.53%
MDNA	44 Neutral	C$61.17M	-5.25	-91.21%	―	―	54.74%
ARCH	26 Underperform	C$66.26M	-41.77	―	―	―	10.49%

Helix BioPharma Corporate Events

Helix BioPharma Reports Fiscal 2025 Results and Strategic Developments

Helix BioPharma Corp. reported a reduced net loss for the fiscal year 2025, reflecting strategic shifts including a focus on L-DOS47 for NSCLC treatment. The company terminated certain research collaborations and closed its Edmonton laboratory to streamline operations. Helix received positive feedback from the FDA on its new study design for L-DOS47 in combination with pembrolizumab, indicating progress in its clinical development. Additionally, the company adjusted its capital strategy by not proceeding with a previous equity facility and completed a private placement to raise funds.